登录    
  
首页 > 期刊论文 > 论文摘要
非小细胞肺癌患者EGFR基因突变状态影响因素的临床分析
         
Clinical analysis of factors influencing EGFR mutation status in patients with non-small cell lung cancer

摘    要
目的:探讨中国人表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变状态与非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的性别、年龄、吸烟状态、是否有肿瘤家族史及组织学类型等因素的相关性。方法:2008年2月-2012年5月,共入组在上海市肺科医院确诊为NSCLC,并进行EGFR基因突变状态检测的患者538例。EGFR基因突变状态应用突变特异性扩增系统(amplification refractory mutation system,ARMS)检测,EGFR基因突变状态与各临床特征的相关性采用Logistic回归分析。结果:本次研究共有220名患者存在EGFR基因突变,EGFR基因突变在女性(P < 0.001)、腺癌患者(P < 0.001)、不吸烟者(P < 0.001)及有肿瘤家族史(P=0.031)患者中的发生率高。多因素回归分析结果显示,病理类型[比值比(odds ratio,OR)=0.035)]、吸烟状态(OR=0.005)及肿瘤家族史(OR=0.027)为EGFR基因突变率的独立影响因子。结论:NSCLC患者中,病理学类型、吸烟状态及肿瘤家族史为EGFR基因突变率的独立影响因子。
标    签 癌,非小细胞肺   受体,表皮生长因子   DNA突变分析   统计学,医学   Carcinoma,non-small cell lung   Receptor,epidermal growth factor   DNA mutational analysis   Statistics,medical  
 
Abstract
Objective: To investigate the associations of the mutation status of epidermal growth factor receptor (EGFR) with the factors including gender,age,smoking status,family history and histological type in patients with non-small cell lung cancer (NSCLC).Methods: From February 2008 to May 2012,538 consecutive NSCLC patients went through the clinical testing for EGFR mutations in Shanghai Pulmonary Hospital were included in this study.Amplification refractory mutation system (ARMS) method was used to detect EGFR mutation status.The relationships between EGFR mutation and potential related factors were evaluated by using Logistic regression model.Results: The activating mutation of EGFR was found in 220 patients.EGFR mutation was more frequently detected in females (P < 0.001),patients with adenocarcinoma (P < 0.001),never-smokers (P < 0.001) and patients with family history of cancer (P=0.031).Multivariate analysis revealed that pathologic type[odds ratio (OR)=0.035)],smoking status (OR=0.005) and family history of cancer (OR=0.027) were independent predictive factors of EGFR mutation.Conclusion: The factors of pathologic type,smoking status and family history of cancer are independent predictive factors of EGFR mutation.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2014.02.008

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 临床研究

基金项目 2013年度上海市卫生和计划生育委员会青年科研资助项目(编号:183);上海市科委"创新行动计划"基础研究重点资助项目(编号:11JC1411300)

收稿日期 2013/10/11

修改稿日期 2013/12/13

网络出版日期

作者单位点击查看


引用该论文: ZHANG Yi-shi,HE Ya-yi,LI Xue-fei,REN Sheng-xiang,ZHAO Chao,ZHOU Cai-cun. Clinical analysis of factors influencing EGFR mutation status in patients with non-small cell lung cancer[J]. Tumor, 2014, 34(2): 147~152
张怡湜,何雅億,李雪飞,任胜祥,赵超,周彩存. 非小细胞肺癌患者EGFR基因突变状态影响因素的临床分析[J]. 肿瘤, 2014, 34(2): 147~152


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12):2893-2917.
 
【2】Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
 
【3】Giaccone G, Gallegos RM, Le CT, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer:a phaseⅡ study[J]. Clin Cancer Res, 2006, 12(20Pt 1):6049-6055.
 
【4】Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall cell lung cancer (OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8):735-742.
 
【5】Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation[J]. Lung Cancer, 2012, 77(2):460-463.
 
【6】Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced nonsmall-cell lung cancer with mutated EGFR:A metaanalysis from six phase Ⅲ randomized controlled trials[J]. Int J Cancer, 2012, 131(5):E822-E829.
 
【7】Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small cell lung cancer treated with erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial[J]. J Thorac Oncol, 2012, 7(11):1653-1660.
 
【8】Zhou S, Ren S, Yan L, et al. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer[J]. Respirology, 2009, 14(5):709-715.
 
【9】Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer:results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer)[J]. Lancet, 2005, 366(9496):1527-1537.
 
【10】Bronte G, Rizzo S, La PL, et al. Driver mutations and differential sensitivity to targeted therapies:a new approach to the treatment of lung adenocarcinoma[J]. Cancer Treat Rev, 2010, 36(Suppl 3):S21-S29.
 
【11】Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21[J]. J Clin Oncol, 2008, 26(26):4268-4275.
 
【12】Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer:molecular analysis of IDEAL/INTACT gefitinib trials[J]. J Clin Oncol, 2005, 23(31):8081-8092.
 
【13】Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J]. J Clin Oncol, 2005, 23(25):5900-5909.
 
【14】Mak RH, Doran E, Muzikansky A, et al. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC[J]. Oncologist, 2011, 16(6):886-895..
 
【15】Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum:from IPASS, a phase Ⅲ study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J]. J Thorac Onco, 2012, 7(1):115-121.
 
【16】Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China[J]. Lung Cancer, 2012, 77(2):371-375.
 
【17】Mai PL, Garceau AO, Graubard BI, et al. Confirmation of family cancer history reported in a population-based survey[J]. J Natl Cancer Inst, 2011, 103(10):788-797.
 
【18】Ren S, Kuang P, Zheng L, et al. Analysis of driver mutations in female non-smoker asian patients with pulmonary adenocarcinoma[J]. Cell Biochem Biophys, 2012, 64(2):155-160.
 
【19】Ren S, Chen X, Kuang P, et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma[J]. Cancer, 2012, 118(22):5588-5594.
 
【20】Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957.
 
【21】Tiseo M, Gelsomiaino F, Boggni D, et al. EGFR and EML 4-ALK gene mutations in NSCLC:a case report of erlotinib-resistant patient with both concomitant mutations[J]. Lung Cancer, 2011, 71(2):241-243.
 
【22】周彩存, 赵印敏, 唐亮, 等.非小细胞肺癌组织表皮生长因子受体基因突变的临床意义[J].肿瘤, 2005, 25(5):458-461.
 
【23】Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program[J]. J Natl Cancer Inst, 1998, 90(14):1039-1071.
 
【24】Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase Ⅱ study of gefitinib for chemotherapynaive patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations[J]. J Clin Oncol, 2006, 24(21):3340-3346.
 
【25】Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib[J]. New Eng J Med, 2004, 350(21):2129-2139.
 
【26】Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676):1497-1500.
 
【27】Luo YH, Wu CH, Wu WS, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs[J]. J Thorac Oncol, 2012, 7(2):299-305.
 
【28】Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer Inst, 2005, 97(5):339-346.
 
【29】Breyer JP, Avritt TG, Mcreynolds KM, et al. Confirmation of the HOXB13 G84E germline mutat ion in fami l ial pros tate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2012, 21(8):1348-1353.
 
【30】Jalkh N, Nassar-Slaba J, Chouery E, et al. Prevalance of BRCA 1 and BRCA 2 mutations in familial breast cancer patients in Lebanon[J]. Hered Cancer Clin Pract, 2012, 10(1):7.
 
【31】Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR[J]. Nat Genet, 2005, 37(12):1315-1316.
 
【32】Ohtsuka K, Ohnishi H, Kurai D, et al. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation[J]. J Clin Oncol, 2011, 29(8):e191-e192.
 
【33】Shih J Y, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced non-small cell lung cancer[J]. Int J Cancer, 2006, 118(4):963-969.
 
【34】Coté ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease:A pooled analysis from the International Lung Cancer Consortium[J]. Eur J Cancer, 2012, 48(13):1957-1968.
 
相关信息
   标题 相关频次
 表皮生长因子受体基因CA简单重复序列多态性与晚期小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂临床疗效间的关系
 8
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 8
 扩增阻滞突变系统法检测非小细胞肺癌微小标本表皮生长因子受体突变
 7
 微RNA-21与BIM蛋白在逆转肺腺癌细胞对EGFR-TKIs耐药中的相互拮抗作用
 6
 胸苷酸合酶基因变数串联重复多态性与培美曲塞治疗晚期非小细胞肺癌疗效相关性分析
 6
 培美曲塞治疗非小细胞肺癌无症状脑转移临床分析
 5
 GRIM-19基因对肺腺癌耐药细胞株A549/DDP药物敏感性及相关基因表达的影响
 4
 Ⅰ~Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系
 4
 cRGD-氧化铁纳米粒的构建及应用于核磁共振成像诊断中的动物研究
 4
 DNA修复基因MMS19单核苷酸多态性与非小细胞肺癌组织学类型的关系
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 Luffin-β靶向融合免疫毒素的构建、表达及对非小细胞肺癌的抑制作用
 4
 表皮生长因子受体信号通路与卵巢癌耐药细胞株SKOV3/DDP相关性的研究
 4
 单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察
 4
 厄洛替尼治疗晚期非小细胞肺癌的临床研究
 4
 非小细胞肺癌组织中血管内皮生长因子表达与树突状细胞分布的关系
 4
 高海拔地区老年非小细胞肺癌患者接受全电视胸腔镜下肺叶切除的安全性和预后分析
 4
 化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性
 4
 硫酸基转移酶1E1基因单核苷酸多态性联合吸烟与肺癌易感性的关系
 4
 人肺腺癌吉非替尼耐药细胞株中微小RNA的表达谱
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 4
 首剂负荷量伊班膦酸钠治疗肺癌转移性骨痛的疗效和安全性分析
 4
 西妥昔单抗联合多西紫杉醇对EGFR-TKI获得性耐药的非小细胞肺癌细胞的作用
 4
 血管内皮生长因子C过表达或抑制表达对人小细胞肺癌NCI-H446细胞生物学行为的影响
 4
 重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察
 4
 多靶点受体酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的Meta分析
 3
 非小细胞肺癌CD44v6表达的免疫组化研究
 3
 ⅠB期非小细胞肺癌中K-ras的表达对辅助化疗预后的影响
 2
 2009年恶性肿瘤临床治疗新进展
 2
 34例卵巢透明细胞癌临床分析
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2